Eupraxia Pharmaceuticals Inc.
EPRX
$5.96
-$0.03-0.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.34% | 236.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.27% | 134.82% | |||
| Operating Income | 1.27% | -134.82% | |||
| Income Before Tax | 24.35% | -162.32% | |||
| Income Tax Expenses | 23.01% | 1,983.33% | |||
| Earnings from Continuing Operations | 24.32% | -162.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -86.14% | 26.25% | |||
| Net Income | 24.28% | -162.70% | |||
| EBIT | 1.27% | -134.82% | |||
| EBITDA | 1.31% | -135.54% | |||
| EPS Basic | 30.81% | -78.03% | |||
| Normalized Basic EPS | 31.51% | -89.03% | |||
| EPS Diluted | 30.81% | -78.03% | |||
| Normalized Diluted EPS | 31.51% | -89.03% | |||
| Average Basic Shares Outstanding | 10.56% | 38.96% | |||
| Average Diluted Shares Outstanding | 10.56% | 38.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||